Beryl Drugs

Which are the latest news on Beryl Drugs?

Why is Beryl Drugs Ltd falling/rising?

As of 09-Aug, Beryl Drugs Ltd's stock price has risen to 24.04, reflecting a 7.85% increase. This rise is driven by strong recent performance, outperforming the Sensex, and positive technical indicators, despite a significant drop in investor participation.

As of 09-Aug, Beryl Drugs Ltd is experiencing a rise in its stock price, currently at 24.04, which reflects an increase of 1.75 or 7.85%. This upward movement can be attributed to several factors. Over the past week, the stock has significantly outperformed the Sensex, gaining 18.72% compared to the benchmark's 0.52%. Additionally, the stock has shown strong performance over longer periods, with a 1-year increase of 21.84% and a remarkable 5-year increase of 138.49%.<BR><BR>Despite opening the day with a loss of 5.7%, the stock reached an intraday high of Rs 26.68, indicating strong buying interest at higher levels. The stock is also trading above its moving averages across various time frames, suggesting a bullish trend. However, it is important to note that there has been a decline in investor participation, with delivery volume dropping significantly by 96.27% compared to the 5-day average. This could indicate some caution among investors despite the overall positive price movement.<BR><BR>Overall, the combination of strong recent performance, positive technical indicators, and high volatility contributes to the rising stock price of Beryl Drugs Ltd.

Should I buy, sell or hold Beryl Drugs Ltd?

When is the next results date for Beryl Drugs Ltd?

The next results date for Beryl Drugs Ltd is 11 August 2026.

The next results date for Beryl Drugs Ltd is scheduled for 11 August 2026.

How big is Beryl Drugs?

As of 10th June, Beryl Drugs Ltd has a market capitalization of 12.00 Cr, with net sales of 18.82 Cr and a net profit of 0.42 Cr over the latest four quarters. The company has shareholder's funds of 9.50 Cr and total assets of 15.95 Cr.

As of 10th June, Beryl Drugs Ltd has a market capitalization of 12.00 Cr and is classified as a Micro Cap company.<BR><BR>In the latest four quarters, Beryl Drugs reported Net Sales of 18.82 Cr and a Net Profit of 0.42 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 9.50 Cr and Total Assets of 15.95 Cr.

Who are in the management team of Beryl Drugs?

The management team of Beryl Drugs consists of Sanjay Sethi (Executive Director and Managing Director), Sudhir Sethi (Chairman and Non-Executive Director), Abhinav Naik (Independent Non-Executive Director), and Shreya Saraf (Independent Non-Executive Director).

The management team of Beryl Drugs includes the following individuals:<BR><BR>1. Sanjay Sethi - Executive Director, Managing Director, and Promoter<BR>2. Sudhir Sethi - Chairman and Non-Executive Director<BR>3. Abhinav Naik - Independent Non-Executive Director<BR>4. Shreya Saraf - Independent Non-Executive Director<BR><BR>If you need more details about their roles or contributions, feel free to ask!

Who are the peers of the Beryl Drugs?

Beryl Drugs' peers include Zenith Health, Ortin Global, Colinz Labs, Unjha Formul., Ganga Pharma., Vivanza Biosci., Decipher Labs, and Saroja Pharma In. Beryl Drugs has a 1-year return of 31.73%, while Ortin Global leads with 62.21% and Vivanza Biosci. lags at -29.75%.

Peers: The peers of Beryl Drugs are Zenith Health, Ortin Global, Colinz Labs, Unjha Formul., Ganga Pharma., Vivanza Biosci., Decipher Labs, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Zenith Health, Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, and the rest. Average management risk is found at Unjha Formul. and Saroja Pharma In. Below Average growth is noted for Zenith Health, Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma., Decipher Labs, and the rest, while Average growth is seen at Vivanza Biosci. and Unjha Formul. Good capital structure is present at Zenith Health, Colinz Labs, and Unjha Formul., while Beryl Drugs, Ortin Global, Ganga Pharma., Vivanza Biosci., Decipher Labs, and Saroja Pharma In have Below Average capital structure.<BR><BR>Return Snapshot: Ortin Global has the highest 1-year return at 62.21%, while Vivanza Biosci. has the lowest at -29.75%. Beryl Drugs' 1-year return of 31.73% is significantly higher than Vivanza Biosci.'s. Additionally, the six-month returns for Zenith Health, Ganga Pharma., Vivanza Biosci., Decipher Labs, and Saroja Pharma In are negative.

What does Beryl Drugs do?

Beryl Drugs Ltd manufactures, sells, and exports branded and generic pharmaceuticals, classified as a Micro Cap company with a market cap of INR 12 Cr. As of March 2026, it reported net sales of 5 Cr and a net profit of 1 Cr.

Overview: <BR>Beryl Drugs Ltd is engaged in the manufacture, sale, and export of branded and generic pharmaceutical formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Beryl Drugs Limited was incorporated on August 24, 1993, and acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 4.25% <BR>Price to Book: 1.24 <BR><BR>Contact Details: <BR>Address: 133 Kanchan Bag, Indore Madhya Pradesh: 452001 <BR>Tel: 91-731-25076375/3046366 <BR>Email: beryldrugs25@yahoo.com <BR>Website: http://www.beryldurgs.com

Are Beryl Drugs Ltd latest results good or bad?

Beryl Drugs Ltd's latest Q4 FY26 results show a positive turnaround with a net profit of ₹0.56 crores and a 35.71% revenue increase, indicating improved operational efficiency. However, concerns about the company's historical volatility and ongoing challenges suggest that caution is warranted despite this strong quarter.

Beryl Drugs Ltd's latest results for Q4 FY26 show a significant turnaround, indicating a positive trajectory in certain areas. The company reported a net profit of ₹0.56 crores, marking a return to profitability after a previous loss of ₹0.17 crores in the prior quarter. Additionally, revenue increased by 35.71% quarter-on-quarter and 29.22% year-on-year, reaching ₹5.13 crores, which reflects a strong recovery.<BR><BR>The operating margin also improved dramatically to 26.12%, the highest in seven quarters, suggesting enhanced operational efficiency. Furthermore, the profit after tax (PAT) margin rose to 10.92%, up from negative figures in the previous quarter.<BR><BR>However, while these results are encouraging, they come with caveats. The company has exhibited significant volatility in its financial performance over the past several quarters, raising concerns about sustainability. The full-year performance remains troubling, with a decline in annual revenue and persistent challenges in profitability.<BR><BR>Overall, while the latest quarterly results are good in isolation, they highlight a dramatic recovery that must be viewed within the context of the company's historical volatility and ongoing operational challenges. Investors should remain cautious, as a single strong quarter does not necessarily indicate a definitive turnaround.

How has been the historical performance of Beryl Drugs?

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25, while total liabilities also fell from 17.39 Cr to 15.95 Cr during the same period. Cash flow from operating activities improved to 2.00 Cr in Mar'25, contrasting with previous years where it was zero. Overall, Beryl Drugs has experienced both growth and decline in various financial aspects, reflecting a complex performance trajectory.

Is Beryl Drugs overvalued or undervalued?

As of September 2, 2025, Beryl Drugs is considered very attractive with a PE ratio of 12.71 and an EV to EBITDA of 7.30, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, despite a challenging year-to-date performance of -29.05%, as it has achieved a 3-year return of 168.59%, significantly outperforming the Sensex.

As of 2 September 2025, Beryl Drugs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 12.71, an EV to EBITDA of 7.30, and a ROCE of 10.96%. In comparison, its peers exhibit significantly higher valuations, such as Sun Pharma with a PE ratio of 32.69 and Divi's Lab at 70.48, indicating that Beryl Drugs offers a more favorable investment opportunity relative to its competitors.<BR><BR>Despite a challenging year-to-date performance of -29.05%, Beryl Drugs has shown resilience with a 3-year return of 168.59%, significantly outperforming the Sensex's 36.32% return during the same period. This suggests that the market may not fully recognize the company's potential, further supporting the conclusion that it is undervalued.

Who are the top shareholders of the Beryl Drugs?

The top shareholders of Beryl Drugs include promoter Sanjay Sethi with 10.88% and public shareholder Samir Narendra Gupta with 4%. Individual investors collectively hold 68.69%, with no institutional holdings or pledged shares reported.

The top shareholders of Beryl Drugs include Sanjay Sethi, who is the promoter with the highest holding at 10.88%. The highest public shareholder is Samir Narendra Gupta, holding 4%. Additionally, individual investors collectively hold a significant portion of the company at 68.69%. There are no institutional holdings or pledged promoter shares reported.

What is the technical trend for Beryl Drugs?

As of February 21, 2025, Beryl Drugs is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and KST, alongside mildly bearish Bollinger Bands and Dow Theory signals.

As of 21 February 2025, the technical trend for Beryl Drugs has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly charts. The Dow Theory shows a mildly bearish stance on the weekly but no trend on the monthly, further supporting the bearish outlook.

Has Beryl Drugs declared dividend?

No Dividend History Available